Asset
AB-101
Arbutus Biopharma Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05960240 | phase1 | completed | 2023-08-30 | 2025-12-04 | Arbutus Biopharma Corporation | Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. |
FDA applications (0)
This company has no applications containing this asset.